Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors

Sreevalsa Appukkuttana Data Generation and Observational Studies, Bayer Healthcare, Whippany, NJ, USACorrespondence[email protected]
View further author information

Gilbert Koa Data Generation and Observational Studies, Bayer Healthcare, Whippany, NJ, USAView further author information

Chunmay Fua Data Generation and Observational Studies, Bayer Healthcare, Whippany, NJ, USAView further author information

Breyanne Bannisterb Market Access & Healthcare Consulting, Cencora, Conshohocken, PA, USAView further author information

Sheldon X. Konga Data Generation and Observational Studies, Bayer Healthcare, Whippany, NJ, USAView further author information

Jay Jhaveria Data Generation and Observational Studies, Bayer Healthcare, Whippany, NJ, USAView further author information

Stephen J. Freedlandc Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Medical Center, Los Angeles, CA, USA;d Section of Urology, Durham VA Medical Center, Durham, NC, USAView further author information

show all

Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date